Zobrazeno 1 - 10
of 125
pro vyhledávání: '"JoAnn, Hsu"'
Autor:
Marice B. Alcantara, Wilson S. Tang, Dongfang Wang, Damian Kaniowski, Elaine Kang, Nazli Dizman, Alexander Chehrazi-Raffle, Luis Meza, Zeynep Zengin, Jeremy Hall, JoAnn Hsu, Colt Egelston, Dayson Moreira, Alan Horsager, Sumanta K. Pal, Marcin Kortylewski
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
IntroductionImmune checkpoint blockade (ICB) improved clinical outcomes in renal and bladder cancer patients, but the response rates remain limited especially in metastatic disease. While STAT3 transcription factor is well-known master regulator of t
Externí odkaz:
https://doaj.org/article/dd84707eb9c14a5ba4ee11901b173fa0
Autor:
Hedyeh Ebrahimi, Dena Battle, Nicholas J. Salgia, Zeynep B. Zengin, Nazli Dizman, Luis Meza, Cristiane D. Bergerot, Regina Barragan-Carrillo, JoAnn Hsu, Daniela Castro, Benjamin Mercier, Neal Chawla, Xiaochen Li, Abhishek Tripathi, Sandy T. Liu, Alex Chehrazi-Raffle, Ulka Vaishampayan, Michael D. Staehler, Sumanta K. Pal
Publikováno v:
Nutrients, Vol 16, Iss 11, p 1630 (2024)
Many patients diagnosed with cancer adopt dietary changes and supplement use, and a growing body of evidence suggests that such modifications can affect outcomes to cancer therapy. We sought to assess the prevalence of these practices and the surroun
Externí odkaz:
https://doaj.org/article/06e6f35dc732492abffa3b9a9898817f
Autor:
Nicholas J. Salgia, Alexander Chehrazi‐Raffle, JoAnn Hsu, Zeynep Zengin, Sabrina Salgia, Neal S. Chawla, Luis Meza, Jasnoor Malhotra, Nazli Dizman, Ramya Muddasani, Nora Ruel, Mary Cianfrocca, Jun Gong, Sidharth Anand, Victor Chiu, James Yeh, Sumanta K. Pal
Publikováno v:
Cancer Medicine, Vol 10, Iss 16, Pp 5671-5680 (2021)
Abstract Background Tertiary cancer centers offer clinical expertise and multi‐modal approaches to treatment alongside the integration of research protocols. Nevertheless, most patients receive their cancer care at community practices. A better und
Externí odkaz:
https://doaj.org/article/3247895c6c634ff285bccc140d3b7306
Autor:
Kyuwan Lee, Lanie Lindenfeld, Meagan Echevarria, JoAnn Hsu, F. Lennie Wong, Hari K. Narayan, Clayton Lau, LiYing Cai, Sumanta K. Pal, Saro H. Armenian, June-Wha Rhee
Publikováno v:
International Journal of Cardiology. 380:40-46
Autor:
Daniela V. Castro, Zeynep B. Zengin, Jasnoor Malhotra, Cristiane D. Bergerot, Luis Meza, Nazli Dizman, Ameish Govindarajan, JoAnn Hsu, Alex Chehrazi-Raffle, Neal Chawla, Benjamin D. Mercier, Sean W. Chen, Matthew Feng, Sweta Prajapati, Kyle O. Lee, Errol J. Philip, Tanya B. Dorff, Yung Lyou, Sumanta K. Pal
Publikováno v:
Cancer Investigation. 41:70-76
Since the approval of the COVID-19 vaccines, their safety and efficacy has been widely demonstrated in patients with cancer. However, there remain patients with reservations regarding vaccination. We aimed to assess genitourinary cancer patients' per
Autor:
Sumanta Pal, Nazli Dizman, JoAnn Hsu, Nicholas Salgia, Milton L Greenberg, Andrew C Newman, Jonathan Skupsky, Zeynep Zengin, Luis Meza, Neal Chawla, Sabrina Salgia, Jasnoor Malhotra
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/c7db408b55554bceb3ba79d95d5e6cbf
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/366ed122ad724be9b7478fddf823ccf5
Autor:
Vadim S. Koshkin, Pedro C. Barata, Tian Zhang, Daniel J. George, Michael B. Atkins, William J. Kelly, Nicholas J. Vogelzang, Sumanta K. Pal, JoAnn Hsu, Leonard J. Appleman, Moshe C. Ornstein, Timothy Gilligan, Petros Grivas, Jorge A. Garcia, Brian I. Rini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-7 (2018)
Abstract Background Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remains unknown as these pa
Externí odkaz:
https://doaj.org/article/bbc492fd73414e95b44026496b015f42
Autor:
Hedyeh Ebrahimi, Daniela V. Castro, Matthew I. Feng, Sweta R. Prajapati, Kyle O. Lee, Elyse H. Chan, Trishita Paul, Ishaan Sehgal, Jalen Patel, Xiaochan Li, Zeynep B. Zengin, Luis Meza, Benjamin D. Mercier, JoAnn Hsu, Ameish Govindarajan, Neal Chawla, Nazli Dizman, Cristiane D Bergerot, Adam Rock, Sandy Liu, Abhishek Tripathi, Tanya Dorff, Sumanta K. Pal, Alexander Chehrazi-Raffle
Publikováno v:
Clinical Genitourinary Cancer.
Autor:
Toni K. Choueiri, Darren Feldman, Robert J. Motzer, Sabina Signoretti, Lauren C. Harshman, James J. Hsieh, Jae Lyun Lee, Sumanta K. Pal, JoAnn Hsu, Fabio A. Schutz, Andre P. Fay, Daniel Y. Heng, J. Connor Wells, Guillermo De Velasco, Daniel Castellano, Eliezer Van Allen, David A. Braun, Xiao X. Wei, Dylan J. Martini, Aly-Khan A. Lalani, Raphael Brandao, Abdallah Flaifel, Stephanie A.M. Wankowicz, Wanling Xie, Dominick Bossé, Rana R. McKay
Programmed death 1 (PD-1) and PD ligand 1 (PD-L1) inhibitors have shown activity in metastatic clear cell renal cell carcinoma (ccRCC). Data on the activity of these agents in patients with non–clear cell RCC (nccRCC) or patients with sarcomatoid/r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc7a3b136f17fc5d33e77f0d7330319b
https://doi.org/10.1158/2326-6066.c.6549214.v1
https://doi.org/10.1158/2326-6066.c.6549214.v1